Powered by 
Translate
Translate
Novus Acquisition and Development Corp. (OTC Markets: (NDEV) is a leading national supplemental health insurance carrier and pioneer in offering cannabis embedded in health plans for recreational and medicinal users. It has sealed a landmark partnership deal with Heya Wellness.
Missouri's Heya Wellness and Novus Cannabis MedPlan have joined forces to revolutionize medical cannabis access across the state, potentially reaching a population of more than 4 million people. With 75% of Missouri's 6 million residents being 21 or older, this alliance presents a significant opportunity to improve patient access and care. Additionally, the partnership has the potential to reach beyond state borders, impacting a broader population of 36 million people in neighboring states.
At the heart of this partnership lies Missouri's unique reciprocity law, which extends the benefits of its medical cannabis program to patients from surrounding states. This provision positions Missouri as an attractive market for Novus, enabling the company to serve a vast patient population beyond Missouri's borders.
"We are thrilled to partner with Heya Wellness to expand access to medical cannabis health plans in Missouri," stated Frank Labrozzi, CEO of Novus Cannabis MedPlan. "Missouri's expanding patient population, coupled with our current sales distribution contracts with PRAM and Compass Health, will boost sales efforts, broaden market coverage, and reach a broader patient base across the Midwest. Heya Wellness, a vertically integrated cannabis company with a robust presence in Missouri, shares Novus's commitment to patient-centric care. Heya Wellness encompasses cultivation facilities, processing facilities, and dispensaries, ensuring a seamless supply chain from seed to sale.
"Heya Wellness is unwavering in its dedication to providing patients with access to the highest-quality medical cannabis products," affirmed Alex Knight, President of Heya Wellness. "Partnering with Novus Cannabis MedPlan is a strategic decision that aligns perfectly with our mission."
The synergistic partnership between Novus Cannabis MedPlan and Heya Wellness is poised to transform the Missouri medical cannabis market. The two companies will collaborate closely to educate patients about the therapeutic potential of medical cannabis while equipping dispensaries with the necessary resources to deliver unparalleled patient care.
Furthermore, Novus's existing sales distribution contracts with PRAM and Compass Health will further amplify the sales effort in the region, ensuring comprehensive market coverage and reaching a broader patient base.
This groundbreaking partnership marks a pivotal moment in Missouri's medical cannabis landscape, fostering greater access, enhanced patient care, and a thriving industry poised for exponential growth.
About Heya Wellness
Heya Wellness is a vertically integrated cannabis company with a profound presence in Missouri. The company encompasses cultivation facilities, processing facilities, and dispensaries, fostering a vertically integrated approach to ensure the highest quality medical cannabis products. Heya remains steadfast in its mission to provide patients with exceptional access to medical cannabis.
About Novus
Further Research:
Novus Acquisition & Development Corp. (NDEV) operates through its subsidiary, WCIG Insurance Services, Inc., offering health insurance and related insurance solutions in states with legal medical marijuana programs. With a robust infrastructure covering various insurance lines, including health, life, and fixed annuities, Novus is a leading health insurance carrier, using two key indicators to gauge value and performance.
The Benefit Monetization Ratio measures the annual total of monetized policies, offset by the operating cost ratio, a Balance Sheet line item derived from Net Asset Value and calculated to the Price Book Value.
Novus' medical cannabis benefits package operates as an outside developer. It does not engage in any activities related to the cultivation, handling, transportation, growth, extraction, dispensing, sale, marketing, vending, delivery, supply, circulation, or trade of cannabis or any substances violating United States law or the Controlled Substances Act. The company adheres strictly to state and federal laws and has no intentions to violate them in the future.
It is important to note that statements regarding specific products have not been evaluated by the United States Food and Drug Administration (FDA) and should not be interpreted as intended to diagnose, treat, cure, or prevent disease. The information provided in press releases and product labels is for informational purposes only and should not be considered a substitute for advice from qualified healthcare professionals.
Novus respects the individual transactions involving cannabis, which are solely between state-licensed dispensaries and registered patients. However, it's worth noting that state laws may conflict with the federal Controlled Substances Act. The current administration has indicated that federal law enforcement agencies will not prioritize prosecuting those complying with state-designated laws concerning medical marijuana usage and distribution. Nevertheless, changes in government policies and consolidation could impact the provider network, and there is no assurance that future administrations will not alter this stance.
While Novus does not engage in the harvest, distribution, or sale of cannabis or cannabis-related products, the company could be affected if there were any shifts in enforcement by federal or state governments concerning existing laws. Such changes could result in significant financial implications for Novus and other industry players.
Forward-Looking Statements
This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future.
Investor Contact Information
855-228-7355
Email: info@getnovusnow.com
